Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

On April 16, 2010, the U. S. Food and Drug Administration (FDA) approved erlotinib tablets (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC) whose disease had not progressed after four cycles of platinum-ba...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Cohen, Martin H., Johnson, John R., Chattopadhyay, Somesh, Tang, Shenghui, Justice, Robert, Sridhara, Rajeshwari, Pazdur, Richard
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2010
Aiheet:
Regulatory Issues: FDA
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227916/
https://ncbi.nlm.nih.gov/pubmed/21148614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0257
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia